UK dry powdered inhaler market is anticipated to grow at a substantial rate of around 1.2% during the forecast period. The dry-powder inhaler (DPI) is used to deliver medication to the lungs in the dry powder form. It finds a significant role to treat respiratory diseases including asthma, bronchitis, emphysema, and COPD. As the prevalence of asthma and other respiratory diseases increases across UK, the demand for dry powdered inhalers is also expected to increase for treatment purposes. As per the International Monetary Fund GDP of the country was $2.9 trillion in 2017. UK comprises England, Scotland, Wales and Northern Ireland. The total population of the country in 2017 was 65 million, out of which about 18% are of the geriatric population. Mortalities related to asthma and COPD are high in UK and due to these a significant investment by the government and people can be forecast in the near future.
To Request a Sample of our Report on UK Dry Powdered Inhaler Market: https://www.omrglobal.com/request-sample/uk-dry-powdered-inhaler-market
UK dry powdered inhaler market is segmented based on type, application, and end-user. Based on the type, preventive, reliever, and long-acting bronchodilators dry powdered inhalers are analyzed. The preventive dry powdered inhaler segment led the global dry powdered inhaler market in 2018. Preventive inhalers are most widely used in the treatment of asthma in children and adults. These inhalers do not entail side effects for long-term use, and exceptionally decreases the possibility of an asthma exacerbation. The preventive inhalers further reduce the airways swelling and hence, are recommended for regular use by the physician. Some of the preventive inhalers available in the market include Budesonide and Fluticasone. Moreover, based on the application, the market has been classified into asthma and COPD diseases. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed.
(Get 15% Discount on Buying this Report)
A full Report of UK Dry Powdered Inhaler Market is Available at: https://www.omrglobal.com/industry-reports/uk-dry-powdered-inhaler-market
UK Dry Powdered Inhaler Market Segmentation
By Type
- Preventive Inhaler
- Reliever Inhaler
- Long Acting Bronchodilators Inhaler
By Application
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
By End-User
- Homecare
- Hospitals and Clinics
Company Profiles
- 3M Co.
- Acorda Therapeutics, Inc.
- Adamis Pharmaceuticals Corp.
- Adherium Ltd.
- AstraZeneca PLC
- Bespak
- Boehringer Ingelheim International GmbH
- Chiesi Farmaceutici S.P.A.
- GF Health
- GlaxoSmithKline PLC
- H&T Presspart Manufacturing Ltd.
- Koninklijke Philips N.V.
- Novartis AG
- Omron Healthcare Inc.
- ResMed Corp.
- Pulmatrix Inc.
- Savara, Inc.
- Teicos Pharma Ltd.
- Teva Pharmaceuticals Industries Ltd.
- Vitalograph Ltd.
Reasons to Buy From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/uk-dry-powdered-inhaler-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
For More Information, Visit Orion Market Research
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
